181 related articles for article (PubMed ID: 35606226)
1. Neutrophil-lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera.
Kwon SS; Yoon SY; Jeong SY; Lee MY; Kim KH; Lee N; Won JH
Nutr Metab Cardiovasc Dis; 2022 Aug; 32(8):1913-1916. PubMed ID: 35606226
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Larsen MK; Skov V; Kjær L; Eickhardt-Dalbøge CS; Knudsen TA; Kristiansen MH; Sørensen AL; Wienecke T; Andersen M; Ottesen JT; Gudmand-Høyer J; Snyder JA; Andersen MP; Torp-Pedersen C; Poulsen HE; Stiehl T; Hasselbalch HC; Ellervik C
Blood Cancer J; 2024 Feb; 14(1):28. PubMed ID: 38331919
[TBL] [Abstract][Full Text] [Related]
3. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
Ahlstrand E; Samuelsson J; Lindgren M; Pettersson H; Liljeholm M; Ravn-Landtblom A; Scheding S; Andréasson B
Eur J Haematol; 2020 Mar; 104(3):271-278. PubMed ID: 31863513
[TBL] [Abstract][Full Text] [Related]
4. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
5. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
6. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
7. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
[TBL] [Abstract][Full Text] [Related]
8. Highly increased risk of fracture in patients with myeloproliferative neoplasm.
Johansson P; Kristjansdottir HL; Johansson H; Jakir A; Mellström D; Lewerin C
Leuk Lymphoma; 2021 Jan; 62(1):211-217. PubMed ID: 32909485
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
Pemmaraju N; Gerds AT; Yu J; Parasuraman S; Shah A; Xi A; Kumar S; Scherber RM; Verstovsek S
Leuk Res; 2022 Apr; 115():106809. PubMed ID: 35220060
[TBL] [Abstract][Full Text] [Related]
10. [State-of-the-art management for essential thrombocythemia and polycythemia vera].
Sugimoto Y
Rinsho Ketsueki; 2021; 62(8):1050-1059. PubMed ID: 34497191
[TBL] [Abstract][Full Text] [Related]
11. Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms.
Lee MW; Yeon SH; Ryu H; Song IC; Lee HJ; Yun HJ; Kim SY; Shin KS; Jo DY
Intern Med; 2022 Dec; 61(23):3483-3490. PubMed ID: 35527026
[TBL] [Abstract][Full Text] [Related]
12. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
13. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as new possible minor criteria for diagnosis of polycythemia vera.
Kim MJ; Kwon SS; Ji YS; Lee MY; Kim KH; Lee N; Park SK; Won JH; Yoon SY
Int J Lab Hematol; 2023 Dec; 45(6):853-859. PubMed ID: 37501518
[TBL] [Abstract][Full Text] [Related]
15. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis.
Gowin K; Verstovsek S; Daver N; Pemmaraju N; Valdez R; Kosiorek H; Dueck A; Mesa R
Leuk Res; 2015 Jul; 39(7):684-8. PubMed ID: 25922307
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.
Abdulkarim K; Samuelsson J; Johansson P; Andréasson B
Eur J Haematol; 2017 Jun; 98(6):577-583. PubMed ID: 28251679
[TBL] [Abstract][Full Text] [Related]
17. Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-based Study.
Montani D; Thoré P; Mignard X; Jaïs X; Boucly A; Jevnikar M; Seferian A; Jutant EM; Cottin V; Fadel E; Simonneau G; Savale L; Sitbon O; Humbert M
Am J Respir Crit Care Med; 2023 Sep; 208(5):600-612. PubMed ID: 37311222
[No Abstract] [Full Text] [Related]
18. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
Falanga A; Marchetti M; Barbui T; Smith CW
Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
[TBL] [Abstract][Full Text] [Related]
19. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
20. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
